CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.
OBJECTIVE
To describe a case of significant CD4+ cell decline despite complete viral suppression in an HIV-positive patient receiving didanosine and valganciclovir.


METHODS
A 68-year-old woman diagnosed with HIV and cytomegalovirus (CMV) enteritis (CD4+ cell count 22 cells/mm(3), viral load 88,898 [4.95 log] copies/mL) was treated with valganciclovir and began lamivudine, didanosine, and lopinavir/ritonavir. Three months later, her viral load was less than 50 copies/mL and CD4+ cell count was 317 cells/mm(3). Over the next 9 months, her viral load remained suppressed, but the CD4+ cell count declined to 83 cells/mm(3) and she experienced ongoing symptoms of didanosine toxicity. Didanosine was replaced with abacavir, leading to a complete CD4+ cell recovery and resolution of symptoms.


CONCLUSIONS
Paradoxical declines in CD4+ cell counts have been reported in HIV-infected patients virally suppressed on tenofovir/didanosine regimens, presumably via inhibition of purine nucleoside phosphorylase (PNP) by tenofovir and enhancement of didanosine toxicity. Ganciclovir and its prodrug valganciclovir also inhibit PNP and increase didanosine concentrations; thus, a similar immunological effect with this combination is possible. This hypothesis is consistent with observations from a historic multicenter CMV retinitis study, where a negative CD4+ cell response was observed in patients receiving ganciclovir, while those treated with foscarnet experienced a CD4+ cell increase and a mortality advantage. Of the subjects who received any type of nucleoside therapy during this study, didanosine use was proportionally higher in the ganciclovir arm versus the foscarnet arm. According to the Naranjo probability scale, our patient experienced a probable adverse reaction associated with the combination of didanosine and valganciclovir.


CONCLUSIONS
Patients receiving didanosine-containing highly active antiretroviral therapy and ganciclovir or valganciclovir for treatment of CMV infection should be monitored for didanosine toxicity and unexpected CD4+ cell loss or failure of CD4+ cell recovery. Reduction of didanosine dosage or substitution with an alternative antiretroviral may be necessary.
Tseng
Alice L
AL
Immunodeficiency Clinic, Toronto General Hospital, Toronto, Ontario, Canada. Alice.tseng@uhn.on.ca
Salit
Irving E
IE
D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects*; D018791:CD4 Lymphocyte Count; D003586:Cytomegalovirus Infections / Q000188:drug therapy; D016049:Didanosine / Q000009:adverse effects*; D004347:Drug Interactions; D005260:Female; D015774:Ganciclovir / Q000009:adverse effects / Q000031:analogs & derivatives*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D000077562:Valganciclovir
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D000077562:Valganciclovir; D016049:Didanosine; D015774:Ganciclovir